![]() |
市场调查报告书
商品编码
1497623
CRISPR 基因编辑市场:按产品、技术、应用和最终用途划分 - 2024-2030 年全球预测CRISPR Gene Editing Market by Offering (Reagents & Consumables, Services, Software & Systems), Technology (Anti-CRISPR Proteins, CRISPR/Cas13, CRISPR/Cas9), Application, End-use - Global Forecast 2024-2030 |
※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。
预计2023年CRISPR基因编辑市场规模为32.5亿美元,2024年达到37.7亿美元,预计2030年将达到96.6亿美元,复合年增长率为16.81%。
CRISPR基因编辑,称为CRISPR-Cas9,是一项突破性技术,允许遗传学家和医学研究人员透过添加、删除或改变部分DNA序列来编辑和改变部分基因组。该技术是最简单、最通用、最准确的基因操作方法之一。遗传疾病盛行率的上升和对个人化医疗的需求不断增加是推动市场成长的因素。此外,生物技术和製药产业对研发的大量投资、政府和监管机构对基因编辑应用的支援在推动市场开拓方面发挥关键作用。然而,脱靶效应、围绕人类种系编辑的伦理问题以及环境中可能出现的意外后果是限制市场成长的重大问题。此外,透过作物设计实现精密农业的进步以及细胞和基因研究方法的增强正在为市场成长创造利润丰厚的机会。
主要市场统计 | |
---|---|
基准年[2023] | 32.5亿美元 |
预计年份 [2024] | 37.7亿美元 |
预测年份 [2030] | 96.6亿美元 |
复合年增长率(%) | 16.81% |
区域洞察
由于美洲地区,尤其是美国和加拿大,遗传疾病和慢性病的盛行率很高,因此非常重视推进 CRISPR 技术。消费者的需求集中在个人化医疗和 CRISPR 新疗法的潜力。美国在 CRISPR 专利方面处于领先地位,主要生物技术公司和着名学术机构都在进行引人注目的研究。欧盟 (EU) 国家拥有强而有力的法律规范指导生物技术的应用,影响消费者的需求和购买行为。一方面,严格法规的存在可以鼓励彻底和安全的开发,但另一方面,它可能会减缓创新和采用。在中东和非洲地区,CRISPR技术仍处于采用的早期阶段。由于经济发展程度和医疗基础设施不同,这些地区的消费者需求和客户行为差异很大。亚太地区是一个多元化且快速发展的 CRISPR 基因编辑市场。在中国,CRISPR技术已获得大量国家和私人投资,推动了大量研究和应用,特别是在医学和农业领域。日本正在这一领域进行大力投资,将技术进步与考虑到社会对基因改造的担忧的法规结合起来。
FPNV定位矩阵
FPNV定位矩阵对于评估CRISPR基因编辑市场供应商的市场定位至关重要。此矩阵提供了对供应商的全面评估,并检验了与业务策略和产品满意度相关的关键指标。这种详细的评估使用户能够根据自己的要求做出明智的决定。根据评估结果,供应商被分为代表其成功程度的四个像限:前沿(F)、探路者(P)、利基(N)和重要(V)。
市场占有率分析
市场占有率分析是一种综合工具,可以对 CRISPR 基因编辑市场供应商的现状进行深入而详细的评估。透过仔细比较和分析供应商的贡献,您可以更深入地了解每个供应商的绩效以及他们在争夺市场占有率时面临的挑战。这些贡献包括整体收益、客户群和其他重要指标。此外,该分析还提供了对该行业竞争性质的宝贵见解,包括在研究基准年期间观察到的累积、分散主导地位和合併特征等因素。有了这些详细信息,供应商可以做出更明智的决策并製定有效的策略,以在市场竞争中保持领先地位。
策略分析与建议
策略分析对于寻求在全球市场站稳脚跟的组织至关重要。对 CRISPR 基因编辑市场当前地位的全面评估使公司能够做出符合其长期愿望的明智决策。此关键评估涉及对组织的资源、能力和整体绩效进行彻底分析,以确定核心优势和需要改进的领域。
[191 Pages Report] The CRISPR Gene Editing Market size was estimated at USD 3.25 billion in 2023 and expected to reach USD 3.77 billion in 2024, at a CAGR 16.81% to reach USD 9.66 billion by 2030.
CRISPR gene editing, referred to as CRISPR-Cas9, is a revolutionary biochemical technology that enables geneticists and medical researchers to edit and modify parts of the genome by adding, removing, and altering parts of the DNA sequence. It is one of the simplest, most versatile, and precise methods of genetic manipulation. The rising prevalence of genetic disorders, along with the increasing demand for personalized medicine, is owing to the market growth. Additionally, significant investments in research and development by biotech and pharma sectors and governmental and regulatory support for gene editing applications play a vital role in fostering market development. However, off-target effects, ethical concerns surrounding human germline editing, and the potential for unintended consequences in the environment are significant issues limiting the market growth. Furthermore, the advancement of precision agriculture through crop design and the enhancement of cellular and genetic research methods create lucrative opportunities for market growth.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 3.25 billion |
Estimated Year [2024] | USD 3.77 billion |
Forecast Year [2030] | USD 9.66 billion |
CAGR (%) | 16.81% |
Regional Insights
In the Americas, particularly the United States and Canada, there is a significant emphasis on the advancement of CRISPR technology due to the high prevalence of genetic disorders and chronic diseases. Consumer needs are focused on personalized medicine and the potential of CRISPR to provide novel treatments. The United States is at the forefront in terms of CRISPR patents, with notable research being conducted by biotech giants and prestigious academic institutions. European Union (EU) countries have a robust regulatory framework guiding biotechnology applications that impact both consumer needs and purchasing behavior. The presence of stringent regulations, encouraging thorough, safe development on the one hand but potentially slowing innovation and adoption on the other. In the Middle East and Africa regions, CRISPR technology is still in the nascent stages of adoption. Due to varying levels of economic development and healthcare infrastructure, consumer needs and customer behavior differ significantly across these territories. The Asia Pacific region presents a diverse and rapidly evolving market for CRISPR gene editing. In China, CRISPR technology is receiving massive state and private investment, pushing forward substantial research and applications, especially in medicine and agriculture. Japan demonstrates a strong investment in the field, aligning its technological advancements with regulations sensitive to public concerns about genetic modification.
Market Insights
The market dynamics represent an ever-changing landscape of the CRISPR Gene Editing Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.
FPNV Positioning Matrix
The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the CRISPR Gene Editing Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the CRISPR Gene Editing Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Recent Developments
Synthego and SeQure Dx Partner to Provide Comprehensive Off-Target Analysis Services for CRISPR-Based Therapeutics Developers
Synthego and SeQure Dx formed a strategic alliance to advance the development of CRISPR therapeutics. This collaboration equips developers with an all-encompassing off-target editing analytic service, leveraging SeQure Dx's distinguished ONE-seq assay technology and Synthego's robust suite of synthetic guide RNAs. The seamless integration of these offerings promises to streamline the therapeutic development cycle, enhancing safety and efficiency while satisfying stringent regulatory standards. [Published On: 2024-01-23]
CRISPR QC Raises USD 10 Million in Series A Financing Round
CRISPR QC, a startup based in San Diego, concluded a Series A funding round with a significant USD 10 million investment. Specializing in assessing CRISPR/Cas9 gene-editing endeavors, CRISPR QC is pioneering the field with its innovative platform that utilizes the CRISPR-Chip, a high-precision biosensor designed to evaluate CRISPR activity accurately. This funding triumph comes from a seed funding round that garnered USD 1.6 million, reflecting growing confidence and interest in CRISPR QC's potential to transform gene editing quality control. [Published On: 2024-01-05]
Newcomer Tome Acquires Replace TX in USD 250 Million Gene Editing Deal
Tome Biosciences announced the acquisition of Replace Therapeutics in a strategic move, accelerating its footprint in the burgeoning gene editing sector. This acquisition underscores Tome's ambition to broaden its disease treatment portfolio and embodies the growing valuation of the gene editing market. Replace's contribution to Tome's suite with its ligase-mediated programmable genomic integration (L-PGI) complements Tome's existing large DNA edits, enhancing the company's capabilities in addressing various genetic conditions with high efficiency and specificity. [Published On: 2024-01-03]
Strategy Analysis & Recommendation
The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the CRISPR Gene Editing Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.
Key Company Profiles
The report delves into recent significant developments in the CRISPR Gene Editing Market, highlighting leading vendors and their innovative profiles. These include Agilent Technologies, Inc., AstraZeneca PLC, Beam Therapeutics Inc., Bio-Rad Laboratories, Inc., Caribou Biosciences, Inc., Cellectis S.A., CRISPR Therapeutics AG, Danaher Corporation, Editas Medicine, Inc., F. Hoffmann-La Roche AG, GeneCopoeia, Inc., GenScript Biotech Corporation, Horizon Discovery Group Ltd. by Revvity, Inc., Inscripta, Inc., Intellia Therapeutics, Inc., Lonza Group Ltd., Mammoth Biosciences, Inc., Merck KGaA, New England Biolabs, Inc., OriGene Technologies, Inc., Prime Medicine, Inc., Qiagen NV, Sherlock Biosciences, Inc., Thermo Fisher Scientific Inc., and ToolGen, Inc..
Market Segmentation & Coverage